NCT03654833CompletedPhase 2
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma. The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- First submitted
- 7 Aug 2018
- Start date
- 28 Jan 2019
- Primary completion date
- 21 Feb 2023
- Lead sponsor
- University of Leicester
- Diseases
- Mesothelioma, Lung cancer
- NCT number
- NCT03654833
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 186
- From 28 Jan 2019 to the primary completion date, 21 Feb 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Uncontrolled CNS disease. Asymptomatic brain metastases are allowed if previously treated with radiotherapy \>28 days prior to starting the investigational agent.
- Patients requiring long term oxygen therapy.
Other illness
- Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission, patients with a diagnosis of basal cell carcinoma of the skin or superficial bladder cancer.
- New York Heart Association Class II or greater congestive heart failure.
- Patients with severe hepatic insufficiency or severe renal impairment.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Each individual MiST drug protocol contains the eligibility criteria specific to the treatment allocated to the patient.
Who the study is looking for
- Histologically confirmed MM with an available biopsy for research purposes
- Male or female patients aged ≥18 years.
- Expected survival of ≥12 weeks or greater
- ECOG PS 0-1
- CT scan chest, abdomen (and pelvis if applicable) confirming disease progression.
- Patients must have received at least one prior line of therapy to include a platinum doublet first-line chemotherapy (within or outside of another clinical trial)
- Willing to consent for molecular screening of archived tumour block (PIS1 \& CF1)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals of Leicester NHS Trust Coordinator of this site? Confirm its status | Leicester | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.